{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:43:49Z","timestamp":1777607029499,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11926-020-00970-z","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T21:11:30Z","timestamp":1606425090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-5545","authenticated-orcid":false,"given":"Kimberly","family":"Showalter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica K.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"issue":"2","key":"970_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/2397198318823122","volume":"4","author":"TA Medsger","year":"2019","unstructured":"Medsger TA, Benedek TG. History of skin thickness assessment and the Rodnan skin thickness scoring method in systemic sclerosis. J Scleroderma Relat Disord. 2019;4(2):83\u20138.","journal-title":"J Scleroderma Relat Disord"},{"key":"970_CR2","unstructured":"Foerster A. Zur pathologischen Anatomie des Scleroma der Haut by Erwachsenen [On the pathologic anatomy of scleroma of the skin in adults]. W\u00fcrzburger Med Ztschr. 1861;2:294\u2013300."},{"issue":"11","key":"970_CR3","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1002\/art.22186","volume":"54","author":"EY Kissin","year":"2006","unstructured":"Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum. 2006;54(11):3655\u201360.","journal-title":"Arthritis Rheum"},{"key":"970_CR4","doi-asserted-by":"crossref","unstructured":"\u2022 Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213\u201321 This review explores definitions of specific types of biomarkers, an understanding of which is essential to an informed discussion regarding biomarker discovery.","DOI":"10.1177\/1535370217750088"},{"issue":"11","key":"970_CR5","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"970_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/art.1780220205","volume":"22","author":"GP Rodnan","year":"1979","unstructured":"Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979;22(2):130\u201340.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"970_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/rheumatology\/kel451","volume":"46","author":"F Verrecchia","year":"2007","unstructured":"Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, et al. Skin involvement in scleroderma--where histological and clinical scores meet. Rheumatology (Oxford). 2007;46(5):833\u201341.","journal-title":"Rheumatology (Oxford)"},{"key":"970_CR8","doi-asserted-by":"crossref","unstructured":"Varga J, Denton CP, Wigley FM. Scleroderma: from pathogenesis to comprehensive management. xx ed. New York; 2012. p. Springer, 689.","DOI":"10.1007\/978-1-4419-5774-0"},{"issue":"1","key":"970_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40674-016-0038-7","volume":"2","author":"ND Morgan","year":"2016","unstructured":"Morgan ND, Hummers LK. Scleroderma mimickers. Curr Treatm Opt Rheumatol. 2016;2(1):69\u201384.","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"6","key":"970_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/BOR.0000000000000118","volume":"26","author":"LK Hummers","year":"2014","unstructured":"Hummers LK. Scleromyxedema. Curr Opin Rheumatol. 2014;26(6):658\u201362.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"970_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00000372-200106000-00022","volume":"23","author":"F Rongioletti","year":"2001","unstructured":"Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol. 2001;23(3):257\u201367.","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"970_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0049-0172(88)90008-X","volume":"17","author":"S Lakhanpal","year":"1988","unstructured":"Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988;17(4):221\u201331.","journal-title":"Semin Arthritis Rheum"},{"key":"970_CR13","first-page":"274","volume-title":"Scleroderma in: Lever\u2019s histopathology of the skin","author":"D Elder","year":"1997","unstructured":"Elder D, Elenitsas R, Jaworsky C, Johnson B. Scleroderma in: Lever\u2019s histopathology of the skin. Philadelphia: Lippincott-Raven; 1997. p. 274\u20138."},{"issue":"3","key":"970_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/00000372-199806000-00003","volume":"20","author":"JE Torres","year":"1998","unstructured":"Torres JE, Sanchez JL. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol. 1998;20(3):242\u20135.","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"970_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/art.1780200410","volume":"20","author":"R Fleischmajer","year":"1977","unstructured":"Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis Rheum. 1977;20(4):975\u201384.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"970_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archderm.1957.01550130080008","volume":"75","author":"H Montgomery","year":"1957","unstructured":"Montgomery H, O'Leary PA, Ragsdale WE Jr. Dermatohistopathology of various types of scleroderma. AMA Arch Derm. 1957;75(1):78\u201387.","journal-title":"AMA Arch Derm"},{"issue":"1","key":"970_CR17","first-page":"84","volume":"25","author":"DE Furst","year":"1998","unstructured":"Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol. 1998;25(1):84\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"970_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13075-020-2127-0","volume":"22","author":"C Correia","year":"2020","unstructured":"\u2022\u2022 Correia C, Mawe S, Lofgren S, Marangoni RG, Lee J, Saber R, et al. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision. Arthritis Res Ther. 2020;22(1):48 This study describes a novel approach to SSc skin histologic assessment: computer vision technology that minimizes bias in quantifying skin fibrosis extent. Change in the Deep Neural Network (DNN)-derived Fibrosis Score was shown to correlate with change in modified Rodnan skin score.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"970_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archderm.1992.01680130051005","volume":"128","author":"AH Rook","year":"1992","unstructured":"Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol. 1992;128(3):337\u201346.","journal-title":"Arch Dermatol"},{"issue":"1","key":"970_CR20","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/ar3267","volume":"13","author":"JT Van Praet","year":"2011","unstructured":"Van Praet JT, Smith V, Haspeslagh M, Degryse N, Elewaut D, De Keyser F. Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther. 2011;13(1):R35.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"970_CR21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/rheumatology\/kew003","volume":"55","author":"J Ziemek","year":"2016","unstructured":"Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology (Oxford). 2016;55(5):911\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"970_CR22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.autrev.2012.02.017","volume":"11","author":"P Martin","year":"2012","unstructured":"Martin P, Teodoro WR, Velosa AP, de Morais J, Carrasco S, Christmann RB, et al. Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis. Autoimmun Rev. 2012;11(11):827\u201335.","journal-title":"Autoimmun Rev"},{"key":"970_CR23","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Showalter K, Spiera R, Magro C, Agius P, Martyanov V, Franks JM, et al. Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. Ann Rheum Dis. 2020. This study compared seven SSc skin histologic features to gene expression and clinical severity and improvement. CD34, aSMA, collagen density, and global histologic severity were associated with the Combined Response Index in Systemic Sclerosis. Fibroblast polarization, defined by aSMA and CD34 immunohistochemical assessments, was found to be associated with a gene expression signature relevant to clinical improvement.","DOI":"10.1136\/annrheumdis-2020-219292"},{"issue":"2","key":"970_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.24249","volume":"60","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578\u201383.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"970_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/art.1780270607","volume":"27","author":"AD Roumm","year":"1984","unstructured":"Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984;27(6):645\u201353.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"970_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","volume":"138","author":"M Hinchcliff","year":"2018","unstructured":"Hinchcliff M, Toledo DM, Taroni JN, Wood TA, Franks JM, Ball MS, et al. Mycophenolate Mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin. J Invest Dermatol. 2018;138(6):1301\u201310.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"970_CR27","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/jid.2013.130","volume":"133","author":"M Hinchcliff","year":"2013","unstructured":"Hinchcliff M, Huang CC, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol. 2013;133(8):1979\u201389.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"970_CR28","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/art.40547","volume":"70","author":"Y Allanore","year":"2018","unstructured":"Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, et al. Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double-blind, randomized, eight-week placebo-controlled study followed by a sixteen-week open-label extension study. Arthritis Rheum. 2018;70(10):1634\u201343.","journal-title":"Arthritis Rheum"},{"key":"970_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","volume":"17","author":"JK Gordon","year":"2015","unstructured":"Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, et al. Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res Ther. 2015;17:213.","journal-title":"Arthritis Res Ther"},{"key":"970_CR30","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/art.41302","volume":"72","author":"M Hinchcliff","year":"2020","unstructured":"Hinchcliff M. Lenabasum for skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2020;72:1237\u201340.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"970_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0190-9622(99)70246-X","volume":"41","author":"DN Enomoto","year":"1999","unstructured":"Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema R, et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol. 1999;41(6):915\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"970_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1067\/mjd.2000.105165","volume":"43","author":"A Morita","year":"2000","unstructured":"Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol. 2000;43(4):670\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"970_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1365-4632.2007.02887.x","volume":"46","author":"M Krishna Sumanth","year":"2007","unstructured":"Krishna Sumanth M, Sharma VK, Khaitan BK, Kapoor A, Tejasvi T. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol. 2007;46(2):218\u201323.","journal-title":"Int J Dermatol"},{"issue":"4","key":"970_CR34","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","volume":"110","author":"RA Nash","year":"2007","unstructured":"Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110(4):1388\u201396.","journal-title":"Blood."},{"issue":"9","key":"970_CR35","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/ard.2008.096123","volume":"68","author":"CP Denton","year":"2009","unstructured":"Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009;68(9):1433\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"970_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/ard.2008.095463","volume":"69","author":"V Smith","year":"2010","unstructured":"Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"970_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"970_CR38","doi-asserted-by":"crossref","unstructured":"Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70(6):1003\u20139.","DOI":"10.1136\/ard.2010.143974"},{"issue":"5","key":"970_CR39","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","volume":"167","author":"S Prey","year":"2012","unstructured":"Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167(5):1138\u201344.","journal-title":"Br J Dermatol"},{"issue":"2 Suppl 76","key":"970_CR40","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):151\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"970_CR41","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015;125(7):2795\u2013807.","journal-title":"J Clin Invest"},{"issue":"10038","key":"970_CR42","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630\u201340.","journal-title":"Lancet."},{"issue":"2","key":"970_CR43","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, Pilot Trial. Arthritis Rheumatol. 2018;70(2):308\u201316.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"970_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.161040","volume":"45","author":"VM Hsu","year":"2018","unstructured":"Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, et al. Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, Parallel-group Study. J Rheumatol. 2018;45(3):405\u201310.","journal-title":"J Rheumatol"},{"key":"970_CR45","doi-asserted-by":"crossref","unstructured":"\u2022 Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, et al. Safety and efficacy of Lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheum. 2020;72(8):1350\u201360. This study is the most recent clinical trial to incorporate skin histology as an exploratory outcome measurement tool.","DOI":"10.1002\/art.41294"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00970-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-020-00970-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00970-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T01:40:53Z","timestamp":1669772453000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-020-00970-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["970"],"URL":"https:\/\/doi.org\/10.1007\/s11926-020-00970-z","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"15 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Showalter reports no disclosures. Dr. Gordon reports receiving funds for the following activities: Research Support: Corbus Pharmaceuticals, Cumberland Pharmaceuticals, and Eicos Sciences, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"3"}}